title: Intricacies and inter-relationships between HIV disclosure and HAART: a qualitative study.
abstract: This study aimed to understand whether and how highly active antiretroviral treatment (HAART) affects views and patterns of disclosure and how disclosure interacts with treatment decisions. One hundred and fifty-two HIV-positive adults (52 MSM, 56 women and 44 IDU men) from four US cities participated in two to three-hour, semi-structured interviews in 1998-99. Results indicate that HAART interacts with and shapes HIV disclosure issues in several ways. Medications may 'out' people living with HIV. Thus, in different settings (e.g. work, prisons, drug rehabs and public situations), some try to hide medications or modify dosing schedules, which can contribute to non-adherence, and affect sexual behaviours. Disclosure of HIV and/or HAART may also result in antagonism from others who hold negative attitudes and beliefs about HAART, potentially impeding adherence. Observable side effects of medications can also 'out' individuals. Conversely, medications may improve appearance, delaying or impeding disclosure. Some wait until they are on HAART and look 'well' before disclosing; some who look healthy as a result of medication deny being HIV-positive. Alternatively, HIV disclosure can lead to support that facilitates initiation of, and adherence to, treatment. HIV disclosure and adherence can shape one another in critical ways. Yet these interactions have been under-studied and need to be further examined. Interventions and studies concerning each of these domains have generally been separate, but need to be integrated, and the importance of relationships between these two areas needs to be recognized.
authors.affiliation: HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, NY 10032, USA. rlk2@columbia.edu
authors.forename: R L
authors.initials: RL
authors.lastname: Klitzman
authors.forename: S B
authors.initials: SB
authors.lastname: Kirshenbaum
authors.forename: B
authors.initials: B
authors.lastname: Dodge
authors.forename: R H
authors.initials: RH
authors.lastname: Remien
authors.forename: A A
authors.initials: AA
authors.lastname: Ehrhardt
authors.forename: M O
authors.initials: MO
authors.lastname: Johnson
authors.forename: L E
authors.initials: LE
authors.lastname: Kittel
authors.forename: S
authors.initials: S
authors.lastname: Daya
authors.forename: S F
authors.initials: SF
authors.lastname: Morin
authors.forename: J
authors.initials: J
authors.lastname: Kelly
authors.forename: M
authors.initials: M
authors.lastname: Lightfoot
authors.forename: M J
authors.initials: MJ
authors.lastname: Rotheram-Borus
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000523:psychology*; D030881:Disclosure; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000523:psychology*; D006304:Health Status; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D036301:Qualitative Research; D011788:Quality of Life